Enterprise Value
549.6M
Cash
241.2M
Avg Qtr Burn
-13.39M
Short % of Float
21.58%
Insider Ownership
3.14%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CABA-201 (4-1BB CD19-CAR T) Details Systemic sclerosis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Myasthenia gravis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Systemic lupus erythematosus, Lupus nephritis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Anti-synthetase syndrome, Immune-mediated necrotizing myopathy, Dermatomyositis , Idiopathic inflammatory myopathy / myositis | Phase 1/2 Data readout | |
DSG3-CAART Details Mucosal Pemphigus Vulgaris | Phase 1 Data readout | |
MuSK-CAART Details Autoimmune disease, Myasthenia gravis | Phase 1 Data readout |